Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-5945
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model ; volume:8 ; number:1 ; day:28 ; month:1 ; year:2008 ; pages:1-9 ; date:12.2008
BMC dermatology ; 8, Heft 1 (28.1.2008), 1-9, 12.2008
- Urheber
-
Rauktys, Aubrey
- Beteiligte Personen und Organisationen
-
Lee, Nancy
Lee, Laifong
Dabora, Sandra L.
SpringerLink (Online service)
- DOI
-
10.1186/1471-5945-8-1
- URN
-
urn:nbn:de:1111-20160709794
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rauktys, Aubrey
- Lee, Nancy
- Lee, Laifong
- Dabora, Sandra L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin inhibits poly(ADP-ribosyl)ation in intact cells
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Nude
Testosterone inhibits the growth of prostate cancer xenografts in nude mice
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin inhibits poly(ADP-ribosyl)ation in intact cells
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Nude
Testosterone inhibits the growth of prostate cancer xenografts in nude mice
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin inhibits poly(ADP-ribosyl)ation in intact cells
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Nude
Testosterone inhibits the growth of prostate cancer xenografts in nude mice
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis